Albumin (human) is a Blood Derivative owned by CSL, and is involved in 1 clinical trial, which was completed.
Human albumin shows its mechanism of action because of its colloidal osmotic and oncoctic properties. The rationale for this is the starling concept of the capillary balance of hydrostatic and oncotic pressure gradients across the capillary walls as the determinant of the fluid i.e. The volume distribution between the intravascular and the interstitial compartment. The 5% concentration is approximately isotonic and isooncotic with normal human plasma and hence the small albumin molecules in AlbuRx play a decisive role in the maintenance of the circulating plasma volume.
The revenue for Albumin (human) is expected to reach a total of $32.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Albumin (human) NPV Report.
Albumin (human) is currently owned by CSL.
Albumin (human) Overview
Human albumin (AlbuRx, Albuminar, Albunate, Beribumin, Albumeon, Alburex, Albumex, Albumina Umana, Alburex AU) is obtained by fractionation of blood plasma. It is a formulated as sterile aqueous solution for intravenous route of administration. 5 % of Human albumin solution is indicated for the treatment of shock, burns, pancreatitis and peritonitis, postoperative albumin loss and hypoproteinemia with an oncotic deficit. Its 25 % solution is indicated for albumin volume deficit, oncotic deficit, shock, burns, adult respiratory distress syndrome, cardiopulmonary bypass, pre- and postoperative hypoproteinemia, third space problems of infectious origin (peritonitis, pancreatitis, mediastinitis or extensive cellulitis), acute liver failure, acute nephrosis, ascites, renal dialysis and hemolytic disease of the newborn. Albuminar is indicated in loss of albumin (burn, etc. nephrotic syndrome) and albumin synthesis reduction (such as cirrhosis) by hypoalbuminemia, and hemorrhagic shock. Albuminar is indicated in the emergency treatment of shock, burns and hypoproteinemia with or without edema.
CSL discovers, develops, manufactures, commercializes and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, respiratory disease, neurological disorders and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venoms and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the US, the UK and other countries. CSL is headquartered in Parkville, Victoria, Australia.
The company reported revenues of (US Dollars) US$10,561.9 million for the fiscal year ended June 2022 (FY2022), an increase of 2.4% over FY2021. The operating profit of the company was US$2,927.4 million in FY2022, compared to an operating profit of US$3,130 million in FY2021. The net profit of the company was US$2,254.7 million in FY2022, compared to a net profit of US$2,375 million in FY2021.
Quick View – Albumin (human)
|Highest Development Stage|